Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

Accent Therapeutics appoints Serena Silver as chief scientific officer as it advances Phase I/II ATX-559 trials for advanced ...

Merck KGaA appoints Miguel Fernández Alcalde as president of its US biopharmaceutical division EMD Serono to strengthen the ...

Minoryx Therapeutics plans to submit European approval for leriglitazone after Phase II NEXUS trial shows 35% disease arrest ...

Santhera Pharmaceuticals gains approval in China for Agamree, the first Duchenne muscular dystrophy therapy available for ...

US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating ...

Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial ...

Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful ...

Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...

Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron ...

Shares of US clinical stage biopharma Candel Therapeutics leapt 166% to $12.25 in pre-market activity today, after it ...